AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line Breast Cancer Therapy

Enhertu is currently approved as a second-line treatment for HER2-positive metastatic breast cancer. The new results for the AstraZeneca and Daiichi Sankyo drug in the first-line setting are important because many patients do not live long enough to receive a second-line cancer therapy. The post AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line…

Read More

Analysis: The No Good, Very Bad Year for UnitedHealth

UnitedHealth Group has had a difficult year marked by a dramatic stock drop, leadership shake-up and mounting regulatory scrutiny. Experts point to its aggressive Medicare Advantage strategy and a rapidly evolving healthcare landscape as key drivers of its challenges. The post Analysis: The No Good, Very Bad Year for UnitedHealth appeared first on MedCity News.

Read More

Links

Impact of the government shutdown on health services.Why do patients with sickle cell disease disproportionately leave hospitals against medical advice?New estimates of upcoding.TrumpRx.“FDA will not be able to accept applications for new drugs, generics, biologics, biosimilars or medical devices that require payment of a user fee while the shutdown is in effect”

Read More